AstraZeneca and insitro Strike AI Drug Discovery Deal for MASH and Heart Disease Worth Up to $1.5 Billion, With Only $40 Million Paid Upfront
AstraZeneca has handed a California biotech a chance at one of the larger artificial intelligence drug discovery deals of the year, but the real money depends on science that has not been done yet. The British drugmaker announced on Thursday, October 15, a multi-year collaboration with insitro to find and develop treatments for metabolic dysfunction-associated … Read more